EMEA-000637-PIP01-09-M01 - paediatric investigation plan

Lanthanum carbonate hydrate

Key facts

• Invented name:
  Fosrenol and associated name Foznol
• Active substance:
  Lanthanum carbonate hydrate
• Therapeutic area:
  Uro-nephrology
• Decision number:
  P/22/2010
• PIP number:
  EMEA-000637-PIP01-09-M01
• Pharmaceutical form(s):
  • Chewable tablet
  • Granules
• Condition(s) / indication(s):
  Hyperphosphataemia
• Route(s) of administration:
  Oral use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  28/11/2011
• Compliance check done:
  No